Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial경증/중등도의 COVID-19 성인 환자에 대한 로피나비르/리토나비르 또는 아르비돌의 효능 및 안전성: 탐색적 무작위 대조 시험Randomized Controlled Trial Published on 2020-05-192022-09-14 Journal: Med (New York, N.Y.) [Category] SARS, 임상, 진단, 치료제, [키워드] adverse event affected antiviral medication approved Arbidol assigned benefit caused Characteristics Chest computed tomography clinical Clinical outcome clinical status clinician comparable Context control group Controlled Controlled trial coronavirus SARS-CoV-2 cough COVID-19 COVID-19 pandemic Deterioration drug effective Efficacy Efficacy and safety enrolled exploratory finding follow-up period funding global pandemic group Guangzhou HIV-1 IMPROVE Influenza Lopinavir/ritonavir Mild moderate Moderate COVID-19 monotherapy no difference novel coronavirus SARS-CoV-2 occurred pathogen Patient patients hospitalized primary endpoint Randomized Randomly receive Respiratory illness responsible Safety SARS-CoV-2 SARS-CoV-2 nucleic acid Scientific community Secondary endpoints Significance standard care supported supportive care tested the disease therapy three group Treatment university virus [DOI] 10.1016/j.medj.2020.04.001 PMC 바로가기 [Article Type] Randomized Controlled Trial